FdaApplication
NDA 021660
Identifiers
- fda_app_no: NDA021660
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL-MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2005-01-07 |
Revenue by product
ABRAXANE
| Period | Revenue |
|---|---|
| Q2 2026 | $55.0M |
| Q1 2026 | $50.0M |
| Q4 2025 | $84.0M |
| Q3 2025 | $74.0M |
| Q2 2025 | $105.0M |
| Q1 2025 | $105.0M |
| Q4 2024 | $174.0M |
| Q3 2024 | $253.0M |
| Q2 2024 | $231.0M |
| Q1 2024 | $217.0M |
| Q4 2023 | $247.0M |
| Q3 2023 | $260.0M |
| Q2 2023 | $258.0M |
| Q1 2023 | $239.0M |
| Q4 2022 | $179.0M |
| Q3 2022 | $177.0M |
| Q2 2022 | $241.0M |
| Q1 2022 | $214.0M |
| Q4 2021 | $305.0M |
| Q3 2021 | $266.0M |
| Q2 2021 | $296.0M |
| Q1 2021 | $314.0M |
| Q4 2020 | $297.0M |
| Q3 2020 | $342.0M |
| Q2 2020 | $308.0M |
| Q1 2020 | $300.0M |
| Q4 2019 | $166.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
| Q1 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ABRAXANE | PACLITAXEL | 100MG/VIAL | POWDER;INTRAVENOUS |
1 product